entrectinib
roche
['sclc', 'lcsm,(-blcsm)', 'entrectinib', 'nsclc']
entrectinib in ros1 nsclc diagnosed through blood-based assay. rr = 81.5% mpfs = 14.8m dor = 16.7m 36% dose reduction (but discontinuation rates low) fusion partners described but no data on clinical significance. #lcsm #asco22 
Thoracic medical oncologist | Consultant @ChelwestFT | Vice Chair @BTOGorg | Skier, when snow permits.